Donate For Public and Patients Store Search

S012 - Acne Treatment Controversies

Friday, March 1; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Assess the impact of acne on patients quality of life and discuss the risk of depression and anxiety in patients on isotretinoin.
  • Define the role of topical acne therapies in treatment regimens, including the significance of concentration and formulation of topical retinoids and benzoyl peroxide.
  • Develop the most cost effective treatment regimens for patients with acne.

Description

In this session, the invited speakers will tackle the tough questions in acne management. Topics covered include why it is important for dermatologist to limit antibiotic usage, what is the latest information on the psychological effects of isotretinoin, and who is at risk of acne scarring and what you can do about it.

Disclosures

  • Del Rosso, James Q., DO: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics Inc. – C(H), I(Grants/Research Funding), SP(H); Almirall – C(H); AnaptysBio – I(Grants/Research Funding); Athenix – I(Grants/Research Funding); BioPharmX – I(Grants/Research Funding); Botanix Pharmaceuticals – I(Grants/Research Funding); Cassiopea S.p.A. – C(H); Celgene Corporation – C(H), I(Grants/Research Funding), SP(H); Cutanea Life Sciences – A(H), I(Grants/Research Funding), SP(H); Dermavant Sciences – A(H); Dermira – C(H), I(Grants/Research Funding), SP(H); Encore Dermatology, Inc. – C(H), SP(H); Ferndale Laboratories, Inc. – C(H); Foamix – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – SP(H); L'Oreal USA Inc. – A(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); Leo Pharma Inc. – C(H), I(Grants/Research Funding); LEO Pharma, US – SP(H); Mayne Pharma Group – A(H), SP(H); Menlo Therapeutics – A(H), I(Grants/Research Funding); Novan – C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H), I(Grants/Research Funding); Othro Dermatologics – SP(H); Pfizer Inc. – A(H), SP(H); Promius Pharma, LLC – I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – E(S), SP(H); Sanofi Genzyme – SP(H); Sebacia, Inc. – C(H), I(Grants/Research Funding); Skinfix, Inc. – C(H); Sol-Gel Technologies – C(H), I(Grants/Research Funding); Sonoma Pharmaceuticals – C(H); Sun Pharmaceutical Industries Ltd. – C(H), I(Grants/Research Funding), SP(H); Unilever Home & Personal Care USA – A(H); Verrica Pharmaceuticals Inc – C(H);
  • Keri, Jonette Elizabeth, MD, PhD: Dermira – A(H); Hoffman-La Roche Ltd. – C(Fees); Ortho Dermatologics – A(H); Pierre Fabre Dermatologie – A(H); Sonoma Pharmaceuticals – A(NC); Sun Pharmaceutical Industries Ltd. – A(H);
  • Reynolds, Rachel Victoria Sabbag, MD: Edwards Lifesciences – C(Fees); Medtronics – C(Fees);
  • Rosamilia, Lorraine L., MD: no financial relationships exist with commercial interests.
  • Tan, Jerry Kim Leng, MD: Abbott Laboratories – A(Grants/Research Funding); Allergan, Inc – I(Grants/Research Funding); Boots – C(H); Eli Lilly and Company – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Galderma Research & Development, LLC – C(H); L'Oréal Research and Innovation – C(H); Lilly ICOS LLC – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Promius Pharma, LLC – A(H); Sun Pharmaceutical Industries Ltd. – A(H); Valeant Pharmaceuticals International – A(H);
  • Thiboutot, Diane M., MD: Cassiopea SpA – C(Fees); Dermira – A(Fees); Galderma Laboratories, L.P. – A(H); Novan – C(Fees); Novartis – C(Fees); Sebcaia, Inc – C(H);
  • Tollefson, Megha M., MD: no financial relationships exist with commercial interests.
  • Zaenglein, Andrea L., MD: Allergan, Inc – I(Grants/Research Funding); Astellas Pharma US, Inc – I(Grants/Research Funding); Innovaderm Research Inc. – I(Grants/Research Funding); Othro Dermatologics – A(H); Pfizer Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding);
Schedule
Friday, March 1
1:00 PM
Dr. Keri / The psychosocial impact of acne
1:20 PM
Dr. Del Rosso / Topical treatments in acne
1:40 PM
Dr. Reynolds / Use of hormonal therapies in acne
2:00 PM
Dr. Zaenglein / Diet and acne
2:20 PM
/ Q & A
2:30 PM
Dr. Tollefson / Issues with isotretinoin
2:50 PM
Dr. Thiboutot / Use of antibiotics in acne
3:10 PM
Dr. Tan / Pathogenesis and management of acne scarring
3:30 PM
Dr. Rosamilia / The costs of acne treatment
3:50 PM
/ Q & A
Event Details
  • Date
    Friday, March 1
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 147B
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Andrea L. Zaenglein, MD, FAAD
Speakers
  • Diane M. Thiboutot, MD
  • James Q. Del Rosso, DO, FAAD
  • Jerry Kim Leng Tan, MD, FAAD - Handout 1, Handout 2, Handout 3
  • Jonette Elizabeth Keri, MD, PhD, FAAD
  • Lorraine L. Rosamilia, MD, FAAD - Handout
  • Megha M. Tollefson, MD, FAAD - Handout
  • Rachel Victoria Sabbag Reynolds, MD, FAAD